## CLAIMS

1. A pharmaceutical composition used for the treatment of malaria comprising the compound of the general formula:

$$R_3$$
 $R_4$ 
 $R_5$ 
 $R_7$ 
 $R_8$ 
 $R_8$ 
 $R_9$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{15}$ 

5

(wherein  $R_1 \sim R_{12}$  is independently hydrogen atom, halogen atom, hydroxyl group, alkyl group, alkoxy group, amino group or acylamino group)

and a pharmaceutically acceptable carrier.

10

2. A pharmaceutical composition of Claim 1 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ , and  $R_{12}$  is hydrogen atom in the compound.

3. A pharmaceutical composition of Claim 2 wherein the compound is 2S, 3R, 2'S- 5,7,5',7'-tetrahydroxy-2,2'-bis- (4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.

15

4. A pharmaceutical composition of Claim 1 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ , and  $R_{12}$  is hydrogen atom and  $R_{11}$  is hydroxyl group in the compound.

- 5. A pharmaceutical composition of Claim 4 wherein the compound is 2S,3R,2'S,3'R-5,7,3',5',7'-pentahydroxy-2,2'-bis-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.
- 6. A pharmaceutical composition of Claim 4 wherein the compound is 2R,3S,2'S,3'R-5,7,3',5',7'-pentahydroxy-2,2'-bis-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro[3,8']bichromenyl-4,4'-dione.
- 7. A pharmaceutical composition of Claim 1 wherein  $R_1$ , 10  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_9$ ,  $R_{10}$ , and  $R_{12}$  is hydrogen atom and  $R_8$  and  $R_{11}$  is hydroxyl group.
  - 8. A pharmaceutical composition of Claim 7 wherein the compound is 2S,3R,2'S,3'R-2'-(3,4-dihydroxyphenyl)-5,7,3',5',7'-pentahydroxy-2-(4-hydroxyphenyl)-2,3,2',3'-tetrahydro-[3,8']bichromenyl-4,4'-dione.

15